Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HLA-A*31:01 allele: influence on carbamazepine treatment

1 Jan 2017

Abstract excerpt

Abstract: Carbamazepine (CBZ) is an effective anticonvulsant that can sometimes cause hypersensitivity reactions that vary in frequency and severity. Strong associations have been reported between specific human leukocyte antigen (HLA) alleles and susceptibility to CBZ hypersensitivity reactions. Screening for HLA-B*15:02 is mandated in patients from South East Asia because of a strong association with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Bullous Skin Diseases
Share to Contact Dermatitis and Allergies
Share to Drug-Induced Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28203102
DOI: 10.2147/pgpm.s108598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HLA-A*31:01 allele: influence on carbamazepine treatmentPMID 28203102Read ↗

Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese PopulationSemantic proximity Read ↗

The risk of cutaneous adverse reactions among patients with the <i>HLA-A* 31:01</i> allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective reviewSemantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateSemantic proximity Read ↗

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.Semantic proximity Read ↗

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.Semantic proximity Read ↗

Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.Semantic proximity Read ↗

Investigation of immunogenetic risk factors for carbamazepine-induced hypersensitivity reactionsSemantic proximity Read ↗

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.Semantic proximity Read ↗

Carbamazepine-induced cutaneous reactions: a simple assay to identify patients carrying the HLA-A*31:01 allele.Semantic proximity Read ↗

Genetic predisposition of life-threatening antiepileptic-induced skin reactions.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.